Patents Assigned to Boehringer Ingelheim Pharmaceuticals, Inc.
  • PYRIMIDINE DERIVATIVES
    Publication number: 20100152167
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicants: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Georg DAHMANN, Frank HIMMELSBACH, Bernd KRIST, Martin LENTER, Alexander PAUTSCH, Gisela SCHNAPP, Martin STEEGMAIER, Helmut WITTNEBEN, Anthony S. PROKOPOWICZ, Walter SPEVAK, Andreas SCHOOP, Steffen STEURER
  • Methods and Compounds for the Diagnosis of Inflammatory Disease and Identification of Pharmacological Agents Useful in the Treatment of Inflammatory Disease
    Publication number: 20100136550
    Abstract: Methods for the diagnosis of inflammatory bowel diseases and the identification of agents useful in the treatment of such diseases based upon the agent's effect on reducing Pim-2 expression.
    Type: Application
    Filed: September 25, 2009
    Publication date: June 3, 2010
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Jun LI, Xiang John LI, Randall W. BARTON
  • Process for making heteroaryl amine intermediate compounds
    Patent number: 7714127
    Abstract: Disclosed are processes to produce a compound of the formula (I):
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: May 11, 2010
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Guisheng Li, Jianxiu Liu, Zhi-Hui (Bruce) Lu, Ming Shen, Sonia Rodriguez, Vittorio Farina
  • Pyrimidine derivatives
    Patent number: 7709480
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: May 4, 2010
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • 1,6 Naphthridines useful as inhibitors of SYK kinase
    Patent number: 7705151
    Abstract: Disclosed are compounds of formula (I): wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: April 27, 2010
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Scott E. Jakes, Joachim Heider, Mark A. Bobko, Renee L. Des Jarlais, Mark Player, James Rinker, Michael Winters, Bao-ping Zhao
  • 1,6 naphthyridines useful as inhibitors of SYK kinase
    Patent number: 7678911
    Abstract: Disclosed are compounds of formula (I): wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: March 16, 2010
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Scott E. Jakes, Joachim Heider, Mark A. Bobko, Renee L. Des Jarlais, Mark Player, James Rinker, Michael Winters, Bao-ping Zhao
  • Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
    Publication number: 20090325988
    Abstract: Compounds of Formula (I) wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Application
    Filed: June 3, 2009
    Publication date: December 31, 2009
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Christian Harcken, Rajashekhar Betageri, Todd Bosanac, Michael Jason Burke, Soojin Kim, Daniel Kuzmich, Thomas Wai-Ho Lee, Zhibin Li, Pingrong Liu, John Lord, Hossein Razavi, Jonathan Timothy Reeves, Daivd Thomson
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Patent number: 7635711
    Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: December 22, 2009
    Assignee: Boehringer-Ingelheim Pharmaceuticals, Inc.
    Inventors: Daniel Kuzmich, Darren DiSalvo, John Robinson Regan, David S. Thomson, Rajashekhar Betageri, Jennifer A. Kowalski
  • Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Patent number: 7622594
    Abstract: Compounds of Formula (IA) and (IB) wherein R1, R2, R3, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: November 24, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Ingo Andreas Mugge, David S. Thomson, Abdelhakim Hammach, Michael Jason Burke, Mark Stephen Ralph, Jennifer A. Kowalski, Joerg Martin Bentzien
  • Fluorescence polarization assay for determining histidine decarboxylase activity
    Patent number: 7608407
    Abstract: The present invention relates to fluorescence polarization assays for determining the HDC modulating activity of a candidate compound including providing a reaction mixture comprising a HDC, histidine, a fluorescently labeled histamine probe, a candidate compound and an anti histamine antibody having selectivity for histamine at least 10 fold greater than histidine: incubating the reaction mixture; and determining whether inhibition of HDC has occurred in the presence of the test compound, wherein an increase in fluorescence signal is an indication that the test compound inhibits the activity of the HDC.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: October 27, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: E. Michael August, Daniel Rajotte
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Patent number: 7601714
    Abstract: Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: October 13, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Antonio J. M. Barbosa, Jr., Steven Richard Brunette, Eugene Richard Hickey, Jin Mi Kim, Michael David Lawlor, René Marc Lemieux, Bryan McKibben, Matt Aaron Tschantz, Hui Yu
  • Cytokine inhibitors
    Patent number: 7592332
    Abstract: Disclosed are compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: September 22, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek Cogan, Daniel R. Goldberg, Ming-Hong Hao, Zhaoming Xiong, Ronald A. Aungst, Amy L. Davis
  • Derivatives of [6,7-dihydro-5-imidazo[1,2-?]imidazole-3-sulfonylamino]-propionamide
    Patent number: 7589115
    Abstract: Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: October 15, 2007
    Date of Patent: September 15, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence Alfred Kelly, Jin Mi Kim, René Marc Lemieux
  • Fluorescent probes for use in protein kinase inhibitor binding assay
    Patent number: 7588899
    Abstract: The invention provides methods relating to a screening assay format that can be applied to broad members of the protein kinase gene family. The assay uses a series of labeled, active site probes described herein that can be displaced by an inhibitor agent. The Kd for the inhibitor compound is derived based on the Kd of the probe for the kinase and the dose response of the inhibitor agent. The invention also provides active site probes suitable for use with the screening method.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: September 15, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Anthony S. Prokopowicz, III, Martha Priscilla Brown, Jessi Marie Wildeson, Scott Jakes, Mark E. Labadia
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Patent number: 7579469
    Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: August 25, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Daniel Kuzmich, Thomas Wai-Ho Lee, John Robert Proudfoot, John Robinson Regan, David S. Thomson, Abdelhakim Hammach, Mark Stephen Ralph, Renee Zindell, Younes Bekkali, Thomas Martin Kirrane, Jr.
  • Cytokine inhibitors
    Patent number: 7569568
    Abstract: Disclosed are compounds of formula (I) Where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: August 4, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek A. Cogan, Ming-Hong Hao, Kevin Chungeng Qian, Alan David Swinamer
  • 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE
    Publication number: 20090171089
    Abstract: Disclosed are compounds of formula (I): wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
    Type: Application
    Filed: March 6, 2009
    Publication date: July 2, 2009
    Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Charles L. CYWIN, Scott E. JAKES, Joachim HEIDER, Mark A. BOBKO, Renee L. DES JARLAIS, Mark PLAYER, James RINKER, Michael WINTERS, Bao-ping ZHAO
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    Patent number: 7553966
    Abstract: Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: June 30, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Rajashehar Betageri, Thomas A. Gilmore, Christian Hanke Justus Joachim Harcken, Daniel Kuzmich, Hossein Razavi, Doris Riether, David S. Thomson, Ji Wang
  • Small molecules useful in the treatment of inflammatory disease
    Patent number: 7550494
    Abstract: Compounds of the formula I which are useful for treating or preventing inflammatory and immune cell-mediated diseases.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: June 23, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Jiang-Ping Wu, Terence Alfred Kelly, Rene M. Lemieux, Daniel R. Goldberg, Jonathan Emillian Emeigh, Ronald John Sorcek
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Patent number: 7550473
    Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: June 23, 2009
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mario G. Cardozo, Derek Cogan, Charles Lawrence Cywin, George Dahmann, Darren DiSalvo, John David Ginn, Anthony S. Prokopowicz, III, Denice M. Spero, Erick Richard Roush Young